Doyle Ramona 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Feb 2, 2022
Insider Transaction Report
Form 4
Doyle Ramona
Chief Medical Officer
Transactions
- Exercise/Conversion
Class A Common Stock
2022-01-31$2.48/sh+15,625$38,750→ 57,335 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-01-31−15,625→ 694,053 totalExercise: $2.48Exp: 2030-12-30→ Class A Common Stock (15,625 underlying)
Footnotes (3)
- [F1]Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person.
- [F2]Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021
- [F3]Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.